REG - SkinBioTherapeutics - Appointment of the Interim CEO to the Board

SkinbiotherapeuticsAnnouncement

09/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260309:nRSI7635Va&default-theme=true

RNS Number : 7635V  SkinBioTherapeutics PLC  09 March 2026

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

 

Appointment of the Interim CEO to the SBTX Board of Directors

 

9 March 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science
business focused on skin health, has confirmed the appointment of Rachel
Parsonage, Interim CEO to the Board of Directors. Her appointment was subject
to normal regulatory due diligence carried out by the Company's Nominated
Adviser, which is now complete.

 

Martin Hunt, Executive Chairman of SkinBioTherapeutics, said:

"Rachel has been in the post of Interim CEO for just a week so far, and
already, she has met the majority of the team and is getting under the skin of
the business, including building relationships with our key partners. Her deep
experience in leading consumer beauty and wellness companies is evident in her
approach, and she has a clear plan of what she wants to achieve in the
immediate near term. In the meantime, we are waiting for the outcome of the
external investigation as well as preparing for the HY results. We will make
further announcements on these events in due course."

-Ends-

 

The following information is disclosed pursuant to rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies:

 

 Full name:                                                                 Rachel Parsonage
 Age:                                                                       51
 Shareholding in SkinBioTherapeutics:                                       Nil
 Current directorships held:                                                Alera Advisory Ltd
 Directorships held in the previous 5 years:                                Knowledge & Merchandising Inc Ltd

KMI Brands Ltd

KMI Brands Inc
 Directorships or Shadow Directorships held in companies that have entered  This Works Limited [Dissolved 20 April 2011]
 administration or insolvency:

                                                                            Knowledge and Merchandising Intellectual Property Limited [Voluntarily
                                                                            dissolved 27 December 2011]

                                                                            Enormous Yes Company Limited

[Voluntarily dissolved 9 February 2016]

                                                                            ILK Limited

[Voluntarily dissolved 2021 and went into administration on 30 June 2023]

 

Thumbnail image

Interim CEO, Rachel Parsonage

 

For more information please contact:

 SkinBioTherapeutics plc                                  ir@skinbiotix.com
 Martin Hunt, Executive Chairman

Emily Bertram, CFO
 Singer Capital Markets (Nominated Adviser & Broker)      +44 (0) 020 7496 3000

Philip Davies

James Todd

Patrick Weaver
 Vigo Consulting                                          +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris                        SkinBio@vigoconsulting.com

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare
(SkinBiotix(®)) and food supplements that harness the gut-skin axis
(AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where
SkinBiotix(®) is being used as an active skin ingredient with the Croda trade
name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting
the symptoms of inflammatory skin conditions, being sold directly and via
Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skincare and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.SkinBioTherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

Background of Rachel Parsonage

Rachel is a seasoned senior executive with over 25 years' experience leading
consumer beauty and wellness businesses through growth and change. She has
held CEO and transformational level leadership roles across owned and licensed
brand portfolios in both domestic and international markets. She has been
involved in financial and business model management, operations and inventory
management, and the strengthening of corporate governance. Rachel has also
worked closely with boards, founders, lenders and partners to navigate periods
of transition.

Currently, Rachel runs her own advisory consultancy, Alera Advisory. Before
then, she was at KMI Brands for over 16 years, rising from Managing Director
to Chief Executive, where she scaled and stabilised a portfolio of owned and
licensed beauty brands. Before then, Rachel was Managing Director at This
Works, a premium British aromatherapy and skincare brand with UK and US focus,
and previously, she was owner of Vita Management, an independent consultancy.
Prior to this, she was General Manager at Pacific Direct, a global hotel
manufacturing amenity company providing brand development for hotels working
with luxury brands, Elemis, Penhaligons and White Company. Rachel is an
alumnus of the Business Growth Programme (BGP), part of Cranfield's Executive
Development Programme.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAAKFBBBBKDNNK



            Copyright 2019 Regulatory News Service, all rights reserved